

Provisional agenda

- 1. Opening of the meeting**
- 2. Adoption of the agenda and method of work**
- 3. Update on activities and budget to implement the workplan**
 - 3.1 presentation by the Secretariat on activities and budget
 - 3.2 opportunity for update on regional activities (optional)
- 4. Update on implementation of the workplan and agreed list of prioritized activities for 2014–2015**
 - (A) Develop recommendations for the health authorities engaged in the detection of substandard/spurious/falsefully-labelled/falsified/counterfeit (SSFFC) medical products and establish a strengthening and tool-generating programme to contribute to Member States' training
 - (B) Create a focal point network for the exchange of information and consultation at large among Member States and establish an ongoing virtual exchange forum
 - (C) Establish a working group to survey the technologies, methodologies and “track and trace” models in place and to be developed to analyse their advantages and disadvantages and to survey the available authentication and detection technologies and methodologies and analyse their advantages and disadvantages
 - (D) Identify WHO areas working on the issue of access to quality, safe, efficacious and affordable medical products and request a report on the current state of affairs
 - (E) Create a working group to develop and leverage existing recommendations for effective risk communication and recommendations for awareness campaigns on substandard/spurious/falsefully-labelled/falsified/counterfeit (SSFFC) medical products and related actions, activities and behaviours
 - (F) A proposal for a study on the public health and socioeconomic impact of substandard/spurious/falsefully-labelled/falsified/counterfeit (SSFFC) medical products
 - (G) Governance, management and secretariat costs to support the above activities

5. **Next provisional list of activities to implement the workplan**
6. **Outcome of the informal technical discussion on element 5(b) of the workplan on the identification of activities and behaviours that fall outside the mandate of the mechanism and language proposals for the remaining issues**
7. **Update on subparagraph 2(11) of resolution WHA67.20 on regulatory system strengthening for medical products**
8. **WHO's participation in the global steering committee for quality assurance of health products**
9. **Review of the Member State mechanism by the Health Assembly in 2017**
10. **Alignment between the terms of office of the Vice-Chairpersons and rotating Chairperson**
11. **Date of the next meeting**
12. **Report of the Member State mechanism to the Sixty-ninth World Health Assembly through the Executive Board at its 138th session**
13. **Closure of the meeting**

= = =